Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Magnani

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Cardiovascular Diabetology|October 15, 2022
Microvascular complications identify a specific coronary atherosclerotic phenotype in patients with type 2 diabetes mellitusRocco A Montone, Dario Pitocco, Filippo Luca Gurgoglione, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Plos One|February 10, 2025
Cross-cultural adaptation and multicentric validation of the Italian version of the Simplified Evaluation of CONsciousness Disorders (SECONDs)Bahia Hakiki, Silvia Pancani, Agnese De Nisco, et al.
Physiology & Behavior|January 7, 2021
Visual fixation in disorders of consciousness: Development of predictive models to support differential diagnosisDavide Sattin, Davide Rossi Sebastiano, Francesca Giulia Magnani, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of Neurology|September 9, 2021
Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019Alberto Raggi, Lorenzo Monasta, Ettore Beghi, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
European Heart Journal|October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Cardiovascular Diabetology|October 15, 2022
Microvascular complications identify a specific coronary atherosclerotic phenotype in patients with type 2 diabetes mellitusRocco A Montone, Dario Pitocco, Filippo Luca Gurgoglione, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Plos One|February 10, 2025
Cross-cultural adaptation and multicentric validation of the Italian version of the Simplified Evaluation of CONsciousness Disorders (SECONDs)Bahia Hakiki, Silvia Pancani, Agnese De Nisco, et al.
Physiology & Behavior|January 7, 2021
Visual fixation in disorders of consciousness: Development of predictive models to support differential diagnosisDavide Sattin, Davide Rossi Sebastiano, Francesca Giulia Magnani, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of Neurology|September 9, 2021
Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019Alberto Raggi, Lorenzo Monasta, Ettore Beghi, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
European Heart Journal|October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Pageof 10